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Eicosanoids are inflammatory mediators primarily generated by hydrolysis of membrane
phospholipids by phospholipase A2 to ω-3 and ω-6 C20 fatty acids that next are converted
to leukotrienes (LTs), prostaglandins (PGs), prostacyclins (PCs), and thromboxanes (TXAs).
The rate-limiting and tightly regulated lipoxygenases control synthesis of LTs while the
equally well-controlled cyclooxygenases 1 and 2 generate prostanoids, including PGs,
PCs, and TXAs. While many of the classical signs of inflammation such as redness,
swelling, pain, and heat are caused by eicosanoid species with vasoactive, pyretic, and
pain-inducing effects locally, some eicosanoids also regulateT cell functions. Here, we will
review eicosanoid production inT cell subsets and the inflammatory and immunoregulatory
functions of LTs, PGs, PCs, and TXAs in T cells.
Keywords: prostaglandins, leukotrienes, cyclooxygenase 2, regulatory T cells, cAMP, immunoregulation effect,
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INTRODUCTION
The eicosanoids constitute a large and expanding family of lipid
signaling molecules derived from ω-3 and ω-6 C20 fatty acids
(Smith, 1989; Funk, 2001). This conversion of membrane phos-
pholipids into potent signaling mediators provides an efficient
way for cells to respond to various stimuli that require a cellular
response. As part of a complex network of regulators control-
ling a number of important physiological properties including
smooth muscle tone, vascular permeability, and platelet aggre-
gation, eicosanoids have also been implicated in a wide array
of pathophysiological processes and diseases, including inflam-
mation, autoimmunity, allergy, HIV, and cancer (Harizi et al.,
2008; Greene et al., 2011; Bertin et al., 2012). While eicosanoids,
in particular prostaglandins, were originally thought of primar-
ily as proinflammatory mediators given their high expression in
inflamed tissues and ability to induce inflammatory symptoms,
this picture has over time become more nuanced. It is now recog-
nized that these lipids can have both pro- and anti-inflammatory
roles by regulating the immune response (Tilley et al., 2001).
While some eicosanoids are produced from eicosapentaenoic
acid (EPA, 20:5 ω-3) (Wada et al., 2007) or dihomo-γ-linolenic
acid (DGLA, 20:3 ω-6), the majority arise from processing
of arachidonic acid (AA, 20:4 ω-6) (Harizi et al., 2008). AA-
derived eicosanoids comprise the P-450 epoxygenase-generated
hydroxyeicosatetraenoic acids (HETEs) and epoxides, the lipoxy-
genase (LOX) – generated hydroperoxyeicosatetraenoic acids
(HPETEs), lipoxins (LXs), and leukotrienes (LTs), and the
cyclooxygenase (COX)-produced prostanoids (see Figure 1 for
overview of biosynthetic pathways). The prostanoids are per-
haps the most well-known class of eicosanoids and include the
prostaglandins (PGs) PGD2, PGE2, and PGF2α as well as prosta-
cyclin (PC/PGI2) and thromboxane (TXA2). Together with the
leukotrienes, the AA-derived prostanoids will be the major focus
of this article.
Constitutive eicosanoid production is normally low, with the
rate-limiting factor being the availability of free fatty acids, in
particular AA. Free fatty acids are generated from membrane
glycerophospholipids by phospholipase A2s (PLA2s) (Kudo and
Murakami,2002; Leslie,2004; Burke and Dennis,2009) in response
to stimuli such as increased Ca2+ levels or phosphorylation (Kudo
and Murakami, 2002). This elevation in intracellular free fatty acid
levels, in particular that of arachidonic acid, then allows eicosanoid
biosynthesis to proceed. In the case of prostanoid biosynthesis,
AA is converted into PGG2 and then PGH2 through the actions
of COX-1 and COX-2 (also known as PGH synthases 1 and 2).
These enzymes act first as cyclooxygenases to create PGG2 and
then as peroxidases to reduce the peroxide in PGG2 to an alco-
hol in PGH2 (Smith et al., 2000, 2011). Both PGG2 and PGH2 are
thought to be transient intermediates and their production consti-
tutes the committed step in prostanoid biosynthesis. PGH2 is then
converted into one of four possible downstream signaling mol-
ecules (Figure 1). Prostacyclin synthase (PGIS) converts PGH2
to PGI2, hematopoietic (H-PGDS) or lipocalin-type (L-PGDS)
PGD2 synthase convert PGH2 into PGD2, TXA2 synthase (TXAS)
converts PGH2 into TXA2, and membrane-bound (mPGES-1 or
-2) or cytosolic (cPGES) PGE2 synthases convert PGH2 into PGE2.
PGF2α can be synthesized through a number of different pathways
(Basu, 2010; Smith et al., 2011).
On the other hand, in leukotriene biosynthesis, AA is not
processed by COX enzymes, but instead by 5-LOX, which with the
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FIGURE 1 | General overview of synthesis pathways for eicosanoids. The
biosynthetic pathway for the arachidonic acid-derived eicosanoids described
in this article. The figure shows the structures of the relevant eicosanoids
(black), and indicates the enzymes involved in their biosynthesis (blue), as well
as the GPCRs through which these eicosanoids signal (red). PGF2α can be
synthesized through a number of different pathways.
help of 5-LOX -activating protein (FLAP) converts AA first into 5-
HPETE and then into LTA4, an inactive intermediate and precursor
for other leukotrienes. LTA4 can either be converted into LTB4 by
LTA4 hydrolase or into LTC4 by LTC4 synthase, which conjugates
a glutathione to LTA4 (Yokomizo, 2011). LTC4 can then be con-
verted sequentially to LTD4 by gamma-glutamyl transpeptidase
and LTE4 by dipeptidases (Brink et al., 2003).
By signaling through their receptors on the surface of T cells,
eicosanoids have an important role in regulating many aspects of
T lymphocyte function, usually through autocrine or paracrine
signaling (Tilley et al., 2001; Sakata et al., 2010a). It has also
recently become evident that T cells provide a source of these
short-lived signaling mediators in compartments such as lymph
nodes and spleen and in lymphoid infiltrates. In the present
review, we will summarize the evidence for the production of
and signaling by these molecules in T cells, especially in the con-
text of the regulation of immunomodulatory or inflammatory
functions.
BIOSYNTHESIS OF AND SIGNALING BY EICOSANOIDS IN T
LYMPHOCYTES
PGG2 AND PGH2
Production of PGG2 and PGH2 proceeds through the actions of
PLA2 and COX-1 or COX-2. While there has been some discus-
sion about which PLA2 variant(s) are most relevant for eicosanoid
biosynthesis, it is generally agreed that cytosolic PLA2α (cPLA2α)
plays a major role in this process, with the Ca2+-independent PLA2
(iPLA2) more involved in membrane homeostasis and secreted
PLA2 (sPLA2) regulating extracellular phospholipids (Murakami
et al., 2011). Expression of cPLA2α in T cells has been controversial,
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with some groups finding no evidence for it in peripheral blood
monocytes (Roshak et al., 2000) while others have observed mRNA
but no effect of inhibiting this enzyme on AA production in Jurkat
T cells (Tessier et al., 2002) and yet others observe this protein both
in Jurkat T cells and peripheral blood lymphocytes (Burgermeis-
ter et al., 2003) (see Figure 1 for overview of biosynthetic enzymes
and Table 1 for their expression in T cells).
Some groups have concluded that other PLA2 variants may
also be active in T cells, with evidence for both iPLA2 (Roshak
et al., 2000; Tessier et al., 2002) and sPLA2 (Tessier et al., 2002)
being present and active in T lymphocytes. Interestingly, an sPLA2
isoform has also been shown to be expressed in and enhance the
function of regulatory T cells (Treg), but this effect was found to be
independent of the enzyme’s catalytic activity (von Allmen et al.,
2009).
Table 1 | Eicosanoid synthesis inT cells.
Synthase Presence inT cells
PLA2 cPLA2α: Jurkat (Tessier et al., 2002; Burgermeister et al.,
2003)
iPLA2: Jurkat, primary T cells (Roshak et al., 2000; Tessier
et al., 2002)
sPLA2: Jurkat (Tessier et al., 2002)
COX-1 CD3+CD4+ primary T cells, Jurkat (Iniguez et al., 1999;
Pablos et al., 1999)
COX-2 CD3+CD4+ primary T cells, Jurkat (Iniguez et al., 1999;
Pablos et al., 1999). Upregulated upon T cell activation
(Feldon et al., 2006). Expressed also in adaptive Tregs
(Mahic et al., 2006)
PGIS Lymphocytes (Merhi-Soussi et al., 2000). No specific
evidence for expression in T cells
PGDS L-PGDS: not present in T cells
H-PGDS: present in primary T cells (Feldon et al., 2006), in
particular activated Th2 and Tc2 cells (Tanaka et al., 2000)
TXAS No direct evidence for expression in T cells. However, the
presence of TXAS products in some T cells indicates that it
may be expressed at low levels (Genaro et al., 1992;
Kabashima et al., 2003)
PGES No direct evidence, but product is present in Tregs, implying
expression (Mahic et al., 2006)
PGFS No evidence for expression in T cells
5-LOX Present in peripheral blood T cells, including naive and
memory CD4+ and CD8+ as well as TCR–γδ cells
(Cook-Moreau et al., 2007). Also T cell lines (Cook-Moreau
et al., 2007)
LTC4S Jurkat (Cook-Moreau et al., 2007), peripheral blood T cells
(Cifone et al., 1995)
LTA4H Jurkat (Cook-Moreau et al., 2007), peripheral blood T cells
(Los et al., 1995)
Alternatively, arachidonic acid can be released from membrane
phospholipids by phospholipase D (PLD) (Liscovitch et al., 2000;
Melendez and Allen, 2002), which has been shown to be inducible
in human T cells (Bacon et al., 1995, 1998; Exton, 1999). Diacyl-
glycerol (DAG) lipase has also been shown to play a role in the
release of AA in lymphocytes (Cifone et al., 1995).
COX-1 and COX-2, which are capable of converting AA into
PGH2, are both expressed in CD3+CD4+ cells and in Jurkat T
cells. COX-1 is expressed constitutively in T cells and does not
change in response to T cell activation (Pablos et al., 1999). In
contrast, COX-2 is normally expressed at low levels but signifi-
cantly upregulated in response to T cell activation (Iniguez et al.,
1999; Pablos et al., 1999; Feldon et al., 2006). A study from this
lab further demonstrated that during differentiation of adaptive
Tregs, these cells also begin expressing COX-2 and producing PGE2
(Mahic et al., 2006).
In the context of a discussion of the cellular localizations
of PLA2 and COX enzymes, it is worth noting that transcel-
lular eicosanoid biosynthesis has recently been proposed as a
mechanism whereby the entire biosynthetic pathway for a given
eicosanoid need not be present in one particular cell. Instead,
the synthesis may begin in one cell, followed by the transfer of
a synthetic intermediate to a different cell where the final prod-
uct is synthesized. PGH2, LTA4, and arachidonic acid have all
been proposed as possible intermediates transported between cells,
suggesting that in some cases, PLA2 (and COX enzymes) could
be present in one cell and the remaining synthases required for
prostanoid or leukotriene synthesis in another (Folco and Mur-
phy, 2006; Sala et al., 2010). For PGH2, it has also been proposed
that two distinct pathways for PGH2 synthesis exist: one for pro-
duction of PGH2 to be converted into downstream prostanoids
in the usual manner and one for production of untransformed
PGH2 to be released for signaling functions.
PGG2 is a transient intermediate in prostanoid biosynthesis,
with a half-life of about 5 min in aqueous solution at 37 °C, pH
7.4 and significantly shorter – on the order of seconds – in plasma
(Corey et al., 1975). Although there have been some suggestions
that PGG2 may have a biological function (Kuehl et al., 1977; Seidel
et al., 2001) it is primarily considered an ephemeral intermediate
without independent signaling functions. There is no evidence for
a signaling role of this species in T cells.
In the case of PGH2, this is also an unstable endoperoxide
species with comparable half-life to that of PGG2 (Corey et al.,
1975). Although no specific receptor has been identified for this
species either, there is some evidence that it can interact with
other prostanoid receptors, including the DP and CRTH2 recep-
tors (Schuligoi et al., 2009) as well as the TP receptor (Saito et al.,
2003). Because of the rapid conversion of both PGG2 and PGH2
to other prostanoid species, however, it has been challenging to
unequivocally prove that there is a direct action of these interme-
diate species on any of the prostanoid receptors. Several of the
receptors thought to be activated by PGH2, in particular CRTH2,
are known to be expressed on T cells, but so far it has not been
demonstrated that PGH2 has a biologically relevant role in activat-
ing these receptors when expressed on T cells in vivo (See Figure 1
for overview of receptors and Table 2 for overview of expression
of eicosanoid receptors in T cells).
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Table 2 | Eicosanoid receptors inT cells.
Receptor Present in whichT cells
IP T lymphocytes (Tilley et al., 2001), in particular Th1 and Th2 (Zhou et al., 2007)
TP T lymphocytes (Tilley et al., 2001). Highly expressed in immature thymocytes (CD4+CD8+ and CD4−CD8−) and present in mature
CD4+ and CD8+ cells (Ushikubi et al., 1993; Kabashima et al., 2003) and in splenic T cells (Ushikubi et al., 1993)
DP1 Th1, Th2, and CD8+ (Tanaka et al., 2004), CD3+ cells in thymus and lymph nodes (Nantel et al., 2004)
DP2/CRTH2 T lymphocytes (Tilley et al., 2001), activated Th2 and Tc2 cells (Hirai et al., 2001; Tsuda et al., 2001; Tanaka et al., 2004)
EP1 T lymphocytes (Tilley et al., 2001), splenic T cells (Nataraj et al., 2001), low expression in peripheral blood naive T cells (Boniface et al.,
2009)
EP2 T lymphocytes (Tilley et al., 2001), splenic T cells (Nataraj et al., 2001), peripheral blood naive T cells, upregulated upon T cell activation
(Boniface et al., 2009)
EP3 T lymphocytes (Tilley et al., 2001), splenic T cells (not α, β isoforms) (Nataraj et al., 2001), low expression in peripheral blood naive T cells
(Boniface et al., 2009)
EP4 T lymphocytes (Tilley et al., 2001), splenic T cells (Nataraj et al., 2001), peripheral blood naive T cells, upregulated upon T cell activation
(Boniface et al., 2009)
FP No evidence for expression in T cells
BLT1 CD4+ and CD8+ effector T cells, particularly after activation (Tager et al., 2003; Islam et al., 2006), small fraction of peripheral blood T
cells, including helper and cytotoxic T cells as well as NKT and γδT cells (Yokomizo et al., 2001; Pettersson et al., 2003; Islam et al., 2006)
BLT2 CD4+ and CD8+ peripheral blood T cells, downregulated upon T cell activation (Yokomizo et al., 2001)
CysLTR1 Small fraction of peripheral blood T cells (Figueroa et al., 2001; Mita et al., 2001), activation induces higher expression (Prinz et al., 2005),
as does IL-4 (Early et al., 2007). Significant amount in resting Th2 cells (Parmentier et al., 2012)
CysLTR2 Small fraction of peripheral blood T cells (Mita et al., 2001). IL-4 and IFN-γ induce expression (Early et al., 2007)
PGI2/PC
Prostaglandin I2 was originally characterized as an inhibitor of
platelet aggregation and a potent vasodilator (Boswell et al., 2011)
and its analogs are used as treatments for pulmonary hypertension
(Olschewski et al., 2004). Recently it has also been shown that this
molecule has important roles in immune regulation (Boswell et al.,
2011) and some studies suggest that treatment with PGI2 analogs
may improve early graft viability in liver transplant patients, partly
by reducing levels of inflammatory cytokines (Barthel et al., 2012).
While PGIS is expressed in some immune cells, in particular fol-
licular dendritic cells (FDCs) (Lee et al., 2005; Boswell et al., 2011),
there is no direct evidence for expression of this synthase in T cells.
It has, however, been shown that lymphocytes are able to pro-
duce PGI2 through a transcellular mechanism when co-cultured
with human vascular endothelial cells (HUVECs) (Merhi-Soussi
et al., 2000) and that a similar mechanism appears to be operating
between platelets and lymphocytes (Wu et al., 1987), although in
neither of these cases were T cells specifically implicated.
The PGI2 receptor, IP, can be either Gs or Gq-coupled, leading to
either increases in intracellular cyclic AMP (cAMP) levels through
Gs-coupling, which can trigger cAMP-PKA signaling pathways or,
through Gq-coupling, to the initiation of other signaling cascades
(Woodward et al., 2011). IP is expressed on T cells, in particular
cells of the Th1 and Th2 lineages (Zhou et al., 2007). Signaling
through the IP receptor on these cells leads to inhibited cytokine
secretion – in particular, IFNγ production in Th1 cells is abrogated
and Th2 cells express less IL-4, IL-10, and IL-13 after IP stimula-
tion. These results are mirrored by studies in IP knockout mice,
where IL-4 and IFNγ production by splenocytes, which includes
some T cells, was significantly higher in sensitized IP KO mice than
in WT mice (Takahashi et al., 2002). With the exception of IL-10,
where other studies have also shown upregulation in response to
IP signaling (Jaffar et al., 2002), these downregulated cytokines
are proinflammatory, and PGI2 is generally considered to be an
anti-inflammatory and immune suppressive prostaglandin.
This inhibitory effect of IP signaling on cytokine production
from Th1 and Th2 cells appears to be mediated by a cAMP-PKA
pathway, since the PKA inhibitor Rp-8-Br-cAMPS significantly
reduces the IP-stimulation induced effects on cytokine produc-
tion. Further, it is accompanied by a reduction in nuclear-factor
kappa-light-chain-enhancer of activated B cells (NF-κB), a tran-
scription factor known to enhance expression of IFNγ and IL-4
(Zhou et al., 2007). While signaling through the IP receptor has
a direct negative regulatory effect on Th1 and Th2 function, it
appears to promote differentiation into the Th17 lineage (Boswell
et al., 2011; Truchetet et al., 2012). This effect is partially due to
a reduction in IL-12 expression and/or an increase in IL-23 from
dendritic cells (DCs) or monocytes, thus perturbing the IL-23 to
IL-12 ratio and favoring Th17 cell differentiation (Boswell et al.,
2011; Truchetet et al., 2012; Zhou et al., 2012). It appears that
this pathway is IP-specific and proceeds through a PKA path-
way (Truchetet et al., 2012). In addition, the favoring of the
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Th17 lineage during T cell differentiation upon IP-stimulation
appears also to be due to inhibited secretion of IL-4 (Zhou et al.,
2012), a cytokine known to promote Th2 and antagonize Th17
development (Boswell et al., 2011).
In addition to its role in regulating T cell differentiation, PGI2
also has an important role in mediating FDC-T cell interactions
in the germinal centers. FDC-produced PGI2 has been shown
both to inhibit T cell proliferation and to protect T cells from
TCR-mediated activation-induced death (AICD) (Lee et al., 2005,
2008), thus improving the current understanding of why T cells
don’t proliferate or undergo AICD in germinal centers.
TXA2 AND TXB2
Thromboxane A2 is a proinflammatory, short-lived (half-life∼30 s
(Remuzzi et al., 1994)) prostanoid primarily produced in platelets,
but also in activated monocytes, macrophages, and DCs (Naru-
miya, 2003) through the actions of thromboxane A2 synthase.
There is limited evidence for TXAS expression in T cells and
this synthase was found to be absent in thymic lymphocytes
(Ushikubi et al., 1993). However, TXA2’s stable and inactive down-
stream metabolite, TXB2, is produced by helper T cells in response
to isoproterenol stimulation (Genaro et al., 1992) and another
study found very low levels of TXB2 produced from CD4+ cells
(Kabashima et al., 2002), suggesting that TXAS could be present
at low levels in certain T cells.
By signaling through the TP receptor, which is coupled to
Gq, TXA2 activates protein kinase C (PKC) and raises intracel-
lular calcium levels (Narumiya, 2003; Woodward et al., 2011).
TXA2 is best known for causing vasoconstriction and platelet
aggregation and promotes fibrosis and scarring by regulating
extracellular matrix protein levels (Thomas et al., 2003). The
TP receptor is known to be highly expressed in immature thy-
mocytes (CD4+CD8+ and CD4−CD8−) and to a lesser extent
in CD4+CD8− and CD4−CD8+ thymocytes (Ushikubi et al.,
1993; Kabashima et al., 2003). Splenic T cells also express lower
amounts of the TP receptor. In line with this, immune regula-
tory functions for TXA2 have been proposed. Signaling through
the TP receptor has been shown to cause apoptosis in immature
thymocytes, in particular in CD4+CD8+ cells (Ushikubi et al.,
1993), suggesting a potential role in T cell maturation. In other
T cell populations, it has been suggested that signaling through
the TP receptor could affect T cell proliferation (Kelly et al., 1979;
Ceuppens et al., 1985), with a recent study showing that TXA2
signaling through the TP receptor inhibits anti-CD3 stimulated
T cell proliferation (Thomas et al., 2003). Interestingly, prolifera-
tion in response to PMA and ionomycin, which produces a robust
intracellular calcium response and bypasses the normal T cell acti-
vation mechanism, is not affected in TP-deficient cells (Thomas
et al., 2003) or in cells treated with a TP agonist (Kabashima et al.,
2003). These results indicate that TXA2 signaling through the TP
receptor may play an important role in the initial activation of T
cells by antigen-presenting cells (APCs), in particular DCs, but not
in the later downstream intracellular signaling. TP signaling fur-
ther attenuates DC-T cell interactions by promoting chemokinesis
of naïve T cells and inhibiting DC-T cell adhesion, thus play-
ing an important role in adaptive immunity (Kabashima et al.,
2003).
Thromboxane A2 signaling has been implicated in anti-graft
immune responses, with allografts eliciting higher levels of TXA2
than isografts (Gibbons et al., 1987). Mice deficient in the TP
receptor have been shown to display weaker anti-allograft immune
responses (Thomas et al., 2003) and blocking TXA2 synthesis
pharmacologically has been shown to reduce alloreactive immune
responses in vitro (Ruiz et al., 1992) and at least temporarily
improve allograft survival and function in vivo by limiting cyto-
toxic T cell activity (Ruiz et al., 1989). On the other hand, in models
of induced unresponsiveness to allografts by thymic injection of
MHC allopeptides, TXA2 signaling abrogation through synthesis
inhibition or receptor antagonists blocked the unresponsive state,
suggesting that TXA2 signaling in the thymus is involved in medi-
ating immune tolerance in this situation, possibly by leading to
apoptosis of alloactivated T cells circulating through the thymus
(Remuzzi et al., 1994). Together, these data suggests an important
role for TXA2-TP signaling in T cells in the thymus, in particular in
T cell maturation, activation by DCs and in anti-allograft immune
responses.
PGD2 AND 15-DEOXY-∆12,14-PGJ2
PGD2 is produced by activated mast cells in response to allergen
exposure and is thought to play an important role in mediat-
ing allergic inflammation by acting as a vasodilator, recruiter of
eosinophils, basophils, and Th2 cells, modulator of Th2 produc-
tion, and bronchoconstrictor (Pettipher et al., 2007). It also has
important roles in regulating sleep, platelet aggregation, smooth
muscle contraction, and reproduction (Saito et al., 2002; Wood-
ward et al., 2011). Beyond mast cells, a few other cell types also
produce PGD2 from PGH2 through one of the two types of
PGD synthase, L-PGDS and H-PGDS (Joo and Sadikot, 2012).
The former is not known to be expressed in T cells, while
the latter is expressed in certain T cells under specific con-
ditions. In particular, activated COX-2-expressing T cells have
been shown to express H-PGDS and thereby produce PGD2
and likely the downstream PGD2 processing product 15-deoxy-
∆12,14-PGJ2 (15d-PGJ2) (Feldon et al., 2006). It appears that
H-PGDS is particularly prevalent in activated Th2 and Tc2 cells
but not Th1 cells (Tanaka et al., 2000; Herlong and Scott, 2006).
As for the synthesis of 15d-PGJ2, no specific synthase has been
described and few details are known about the dehydration
steps leading to its formation from PGD2 (Scher and Pillinger,
2005).
PGD2 can signal through either the DP1 or DP2/CRTH2 recep-
tor, while 15d-PGJ2 signals through the DP2 receptor (Harris et al.,
2002a; Schuligoi et al., 2010). The DP1 receptor is Gs-coupled
and its activation leads to increases in intracellular cAMP and
PKA activation and can also lead to increased intracellular cal-
cium levels (Woodward et al., 2011). This receptor was shown to
be expressed in certain malignant T cell lines (Harris and Phipps,
2002), but was not detected in normal peripheral blood T cells in
this study (Harris and Phipps, 2002). However, other groups have
found DP1 to be constitutively expressed in both Th1, Th2 and
CD8+ cells (Tanaka et al., 2004) and to be present in CD3+ cells
in the thymus and lymph nodes (Nantel et al., 2004). CRTH2 has
little sequence homology with other prostanoid receptors, being
more closely related to the N -formyl peptide receptor subfamily
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of receptors (Hirai et al., 2001). This receptor is Gi-coupled, lead-
ing to increases in intracellular calcium and inhibition of cAMP
formation in response to signaling (Hirai et al., 2001). It is thought
to be mainly expressed in activated Th2 and Tc2 cells (Tsuda et al.,
2001; Tanaka et al., 2004) and has also been detected in a subset
of infiltrating T cells in patients suffering from polyposis, a severe
form of rhinosinusitis (Nantel et al., 2004). Interestingly, when
heterologously expressed, DP and CRTH2 can form heterodimers,
where DP enhances the signaling by the CRTH2 receptor. In these
heterodimers, when DP signaling is pharmacologically blocked,
CRTH2 function is also inhibited, but not vice versa (Sedej et al.,
2012). In addition to signaling through the cell surface receptors
DP1 and CRTH2, 15d-PGJ2 and PGD2 can also bind the nuclear
hormone receptor transcription factor peroxisome proliferator-
activated receptor gamma (PPAR-γ) (Forman et al., 1995; Kliewer
et al., 1995; Harris et al., 2002a; Feldon et al., 2006). By activat-
ing PPAR-γ, these prostanoids induce differentiation of fibroblasts
into fat cells, and it has been shown that this can be pathophys-
iologically relevant. For instance, in the case of Graves’ disease,
activated T cells infiltrate the eye orbit and by producing PGD2 and
15d-PGJ2, cause the differentiation of fibroblasts in the eye orbit
to adipocytes, leading to disfiguration and sometimes blindness
(Feldon et al., 2006).
Both PGD2 and 15d-PGJ2 affect cytokine production from
T cells. In particular, 15-dPGJ2 is often thought of as an anti-
inflammatory prostaglandin, in part due to its enhancement of
PPARγ’s anti-inflammatory effects (Harris et al., 2002a; Scher
and Pillinger, 2005). However, 15-dPGJ2 can also induce secre-
tion of IL-8, a cytokine with chemotactic and angiogenic effects,
from activated T cells, suggesting a proinflammatory role of this
prostaglandin as well (Harris et al., 2002b). This effect is not PPAR-
γ-dependent, but instead proceeds through a mitogen-activated
protein kinase (MAPK) and NF-κB pathway, possibly by first
binding an extracellular receptor such as CRTH2.
PGD2 has a well-established role in regulating cytokine secre-
tion from Th2 cells. In particular, PGD2 produced in mast
cells stimulates IL-4, IL-5, and IL-13 secretion from Th2 cells
and this process is believed to be important in the patho-
physiology of allergic inflammations (Xue et al., 2009a). It has
been demonstrated that phosphoinositide 3-kinase (PI3K) and
Ca2+/calcineurin/nuclear factor of activated T cells (NFAT) sig-
naling pathways downstream of CRTH2 are both important in
regulating PGD2-induced cytokine production (Xue et al., 2007)
and that LTE4 enhances the PGD2-CRTH2-mediated secretion
of cytokines from Th2 cells (Xue et al., 2012). Another study
confirmed the effect of PGD2 receptor signaling on cytokine
secretion and further noted that while signaling through CRTH2
increases secretion of IL-2, IL-4, IL-5, and IL-13 as well as the
proinflammatory proteins CD11b and CD40L in Th2 cells, sig-
naling through DP1 reduces the number of CD4+ and CD8+
cells expressing IFNγ and IL-2 (Tanaka et al., 2004). By thus
promoting Th2 function and suppressing Th1 functions, PGD2
signaling may have an overall effect of promoting Th2 func-
tion, which could be relevant in allergic responses, where Th2
activity is elevated. PGD2 can have further inhibitory effects
on cytokine secretion, for instance in invariant natural killer
T (iNKT) cells, where PGD2 signals through DP1 and PKA to
inhibit the production of IFNγ, but not IL-4, the other major
cytokine produced in this cell type (Torres et al., 2008). Thus,
PGD2 signaling also contributes to regulating the innate immune
system.
While signaling through PGD2 receptors apparently has a role
in driving Th2-type processes as described above, 15-dPGJ2 may
have a role in resolving certain Th1-driven responses by inhibiting
the proinflammatory NF-κB pathway (Trivedi et al., 2006). Also,
15-dPGJ2 is able to inhibit IL-2 production in T cells by promoting
an interaction between PPARγ and NFAT, a crucial transcription
factor for IL-2 production, which prevents NFAT from binding to
the IL-2 promoter (Yang et al., 2000).
Aside from pro- and anti-inflammatory effects of PGD2 and
15-dPGJ2 mediated by cytokine secretion, these prostaglandins
also affect T cell function by regulating proliferation and apopto-
sis. Both PGD2 and 15-dPGJ2 are capable of inducing apoptosis
in T cells through a PPARγ-dependent mechanism (Harris and
Phipps, 2001, 2002; Harris et al., 2002b). It has also been reported
that 15-dPGJ2 and to a lesser extent PGD2 can induce apoptosis in
Jurkat T cells through a non-PPARγdependent mechanism involv-
ing activation of the mitochondrial apoptosis pathway (Nencioni
et al., 2003). In other situations, PGD2 can also have anti-apoptotic
effects. For instance, in the case of apoptosis induced by cytokine
deprivation, PGD2 signaling through the CRTH2 receptor inhibits
apoptosis in Th2 cells, suggesting that this pathway may hinder res-
olution of allergic inflammation (Xue et al., 2009b). In T lympho-
cytes, 15-dPGJ2 can also inhibit proliferation by acting as a PPARγ
ligand (Clark et al., 2000;Yang et al., 2000; Harris and Phipps, 2001;
Nencioni et al., 2003). However, only TCR-mediated and not IL-2
induced proliferation is affected by 15-dPGJ2 treatment (Clark
et al., 2000).
Signaling through the PGD2 receptors also plays an important
role in the chemotaxis of T cells. When PGD2 acts on the CRTH2
receptor on Th2 cells, this induces chemotactic migration of the
Th2 cells (Hirai et al., 2001), probably through a PI3K pathway
(Xue et al., 2007), providing a possible mechanism for recruit-
ment of Th2 cells to sites of allergic inflammation, for instance in
asthma (Luster and Tager, 2004). It has been demonstrated that
blocking the CRTH2 receptor pharmacologically inhibits the traf-
ficking of lymphocytes, including T cells, to the inflamed airways
in a model of chronic obstructive pulmonary disease (COPD),
presenting a possible new strategy for treating this disease (Steb-
bins et al., 2010). Further chemoattractive effects of PGD2 on T
cells is the CRTH2-mediated recruitment of Th2 and Tc2 cells
to the materno-fetal interface, where they are thought to increase
in early pregnancy (Saito et al., 2002) and PGD2’s ability to pro-
mote transendothelial migration of memory T cells across blood
vascular endothelial cells and lymphatic vascular endothelial cells
(Ahmed et al., 2011).
PGE2
PGE2 is the most abundant prostanoid found in the body and
has important roles in reproduction, gastro-intestinal function,
the immune system, cardiovascular function, and the central ner-
vous system (Sreeramkumar et al., 2012). It is present in large
amounts in many cancers, in particular colorectal and lung can-
cers, where it stimulates tumor growth by inhibiting apoptosis,
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inducing Tregs and promoting metastasis, cell invasion, and angio-
genesis (Bergmann et al., 2007; Wang et al., 2007; Greenhough
et al., 2009; Mandapathil et al., 2010; Brudvik et al., 2011; Nakan-
ishi et al., 2011). PGE2 is produced from PGH2 through one of
three different PGE2 synthases – cytosolic (cPGES) or micro-
somal (mPGES-1 and mPGES-2). While cPGES and mPGES-2
are constitutively expressed, mPGES-1 is inducible in response
to mitogenic or proinflammatory stimuli and is often upregu-
lated in concert with COX-2 (Scher and Pillinger, 2005). In terms
of expression in T cells, little is known except that it has been
demonstrated that adaptive Tregs express COX-2 and produce
PGE2 upon differentiation (Mahic et al., 2006), implying that they
must also express a PGES. This production of PGE2 from adap-
tive Tregs has implications both in cancer and chronic infectious
diseases.
PGE2 can signal through any of its four receptors – EP1, EP2,
EP3, EP4 – often with opposing effects (Breyer et al., 2001; Har-
ris et al., 2002a; Woodward et al., 2011; Sreeramkumar et al.,
2012). EP2 and EP4 receptors are Gs-coupled and lead to increased
intracellular cAMP levels and PKA signaling. The EP1 receptor
is Gq-coupled and results in increased intracellular calcium lev-
els. In the case of the EP3 receptor, three main isoforms of this
receptor exist – EP3 α, β, and γ – and they can signal through dif-
ferent G proteins, but it appears that the major pathway is through
Gi, which leads to decreased intracellular cAMP levels. Messen-
ger RNA for all the different PGE2 receptors, with the exception
of the EP3 α and β isoforms, is present in murine splenic T cells
(Nataraj et al., 2001). In naive T cells isolated from peripheral
blood, EP2 and EP4 receptors appear to be the most abundant and
are upregulated in response to activation (Boniface et al., 2009).
Through its receptors, PGE2 controls T cell function in a variety
of ways and a number of recent reviews have addressed this topic
(Harris et al., 2002a; Brudvik and Tasken, 2012; Sreeramkumar
et al., 2012). First, it appears to differentially regulate apopto-
sis in T cells depending on the subpopulation and condition of
the cells. In particular, CD4+CD8+ thymocytes undergo apop-
tosis when stimulated by PGE2 in vivo (Mastino et al., 1992), but
may also be protected against activation-induced cell death by
this prostanoid (Goetzl et al., 1995). Similarly, while apoptosis is
stimulated in resting mature T cells (Pica et al., 1996), activation-
induced cell death is inhibited (Porter and Malek, 1999; Pace et al.,
2007). PGE2 also has other known negative regulatory functions
in T cells. It is known to influence the function of CD8+ cells
through the inhibitory complex CD94/NKG2A (Zeddou et al.,
2005) and the cytotoxicity of gamma delta T cells through a
cAMP-PKA pathway (Martinet et al., 2010). An anti-proliferative
effect is also well documented. Through the EP2 (Nataraj et al.,
2001) and possibly the EP4 (Kabashima et al., 2002) receptor,
PGE2 can inhibit T cell proliferation in CD4+ and CD8+ cells
(Goodwin et al., 1977; Hendricks et al., 2000). It has also been
shown that PGE2 inhibits the proliferation of double-negative
Tregs (Lee et al., 2009). It appears that proliferation is inhibited
in these cells by a negative regulatory effect of increased intra-
cellular cAMP levels resulting from EP2 or EP4 stimulation on
IL-2 synthesis and IL-2 receptor expression, resulting in dimin-
ished IL-2-stimulated proliferation responses (Farrar et al., 1987;
Mary et al., 1987; Rincon et al., 1988; Anastassiou et al., 1992).
Other possible mechanisms of inhibition of proliferation include
downregulation of the transferrin receptor (Chouaib et al., 1985),
inhibiting intracellular Ca2+ increase and inositol phosphate
production in response to T cell activation (Chouaib et al., 1987;
Lerner et al., 1988; Choudhry et al., 1999) and preventing K+
movements which would dampen signaling via G proteins (Bastin
et al., 1990).
Recent studies have provided additional information about the
intracellular signaling pathways initiated by PGE2 through which
T cell function and proliferation is affected. In particular, a com-
bined phosphoflow/phosphoproteomics approach allowed for the
collection of detailed information about phosphorylation cascades
initiated in response to different amounts of PGE2 stimulation in
different T cell populations (Oberprieler et al., 2010). Further-
more, a pathway was described in effector T cells where signaling
through EP2 or EP4, with its concomitant increase in cAMP lev-
els, leads to PKA activation and, through an EBP50-Ezrin-PAG
scaffolded process, phosphorylation of the C-terminal Src kinase
(Csk). Phosphorylated Csk in turn inhibits Lck-mediated phos-
phorylation of the TCR complex, thus inhibiting TCR signaling
and T cell proliferation and function (Vang et al., 2001; Rup-
pelt et al., 2007; Mosenden and Tasken, 2011) (see Figure 2 for
schematic depiction of the PGE2-cAMP-PKA-Csk inhibitory path-
way in T cells). This pathway is of particular relevance during
inflammatory responses or cancer, where production of PGE2
is increased. It has been shown that disrupting this pathway
in cells by molecular or genetic means prevents PGE2 – medi-
ated inhibition of effector T cell function (Carlson et al., 2006;
Ruppelt et al., 2007; Stokka et al., 2010). In mice, disrupting
this pathway by overexpressing a PKA anchoring disruptor also
leads to an increase in effector T cell function, as evidenced by
increased signaling, enhanced IL-2 secretion, and reduced sen-
sitivity to PGE2-mediated inhibition of T cell function. These
mice also have improved resistance to murine AIDS, an immun-
odeficiency disease induced by the murine leukemia virus where
the PKA-Csk pathway is hyperactivated (Mosenden et al., 2011).
In mice with murine AIDS, this pathway can also be targeted
with COX-2 inhibitors (Rahmouni et al., 2004). Interestingly,
the PKA-Csk pathway is upregulated in several immunodefi-
ciency diseases, as well as cancer, suggesting that targeting this
pathway may be of therapeutic interest (Rahmouni et al., 2004;
Brudvik and Tasken, 2012; Brudvik et al., 2012). In particu-
lar, targeting this pathway with COX-2 inhibitors in patients
with HIV infection appears to give significant patient benefit in
clinical intervention trials as evident from regulation of surro-
gate parameters such as CD38 and immune function parame-
ters such as lymphoproliferation and T cell-dependent vaccine
responses (Johansson et al., 2004; Kvale et al., 2006; Pettersen et al.,
2011).
As described above, PGE2 can influence the production and
secretion of IL-2 from T cells, but it also influences the production
of many other cytokines and contributes to T cell differentiation.
In particular, it has been proposed that PGE2 signaling promotes
a Th2 cell fate (Betz and Fox, 1991). In line with this, PGE2
has been shown to downregulate expression of IFNγ in T cells
(Aandahl et al., 2002), indicating less differentiation to a Th1
cell type, with the caveat that recent studies have shown that in
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FIGURE 2 | Inhibitory pathway of PGE2 in effectorT cells. PGE2
mediates Treg inhibition of effector T cell function through a
PKA-mediated pathway. (A) In response to continuous antigen exposure,
for instance in cancer and HIV, adaptive regulatory T cells express COX-2
and produce PGE2, which stimulates FOXP3 expression in these cells.
The Treg-derived PGE2 can signal through the EP2 and EP4 receptors on
effector T cells to inhibit the function of these cells through the pathway
shown in (B). Binding of PGE2 to its receptors on effector T cells
stimulates adenylyl cyclase activity, which increases intracellular cAMP
levels and thus activates PKA. Aided by an Ezrin-EBP50-PAG scaffold,
PKA phosphorylates Csk, which in turn phosphorylates Lck to inhibit its
activity. Lck normally acts to promote TCR signaling; thus Lck inhibition
through this PGE2-initiated pathway inhibits TCR signaling in effector T
cells.
the presence of strengthened TCR stimulation, the Th1 cell fate
can actually be promoted by PGE2 (Yao et al., 2009). In contrast,
Th2-derived cytokines including IL-4, IL-5, IL-10, and IL-13 are
unaffected or upregulated in response to PGE2 signaling (Betz
and Fox, 1991; Snijdewint et al., 1993; Demeure et al., 1997).
Furthermore, the IL-12 receptor is downregulated on T cells in
response to PGE2, further promoting a Th2 cell fate (Wu et al.,
1998). PGE2 has also been proposed to play a role in the dif-
ferentiation of Th17 and Tregs. There is some debate about the
role of PGE2 in the differentiation and expansion of Th17 cells
(Sakata et al., 2010b), with some studies finding an inhibitory
role in mouse Th17 differentiation (Chen et al., 2009) and others
finding a promoting role in human Th17 differentiation (Boni-
face et al., 2009). There seems to be general agreement that Th17
IL-23-mediated expansion is enhanced by PGE2, however (Chiz-
zolini et al., 2008; Boniface et al., 2009; Napolitani et al., 2009).
In Treg differentiation the majority of reports seem to suggest an
enhancing effect (Baratelli et al., 2005; Sharma et al., 2005; Mahic
et al., 2006; Bryn et al., 2008), although some have found PGE2
to have an inhibitory effect on this process (Chen et al., 2009).
Due to its role in promoting Treg differentiation and inhibiting
effector T cell function and proliferation, PGE2 has traditionally
been considered an immunosuppressant, but with recent stud-
ies showing a possible enhancing effect of this eicosanoid on
Th17 and Th1 differentiation, some have argued that the pic-
ture is more nuanced (Sakata et al., 2010b; Sreeramkumar et al.,
2012).
PGF2α
PGF2α has important functions in reproduction, inflammation,
cardiovascular function, and other (patho)physiological processes
(Simmons et al., 2004; Basu, 2007, 2010; Woodward et al., 2011).
This prostaglandin can be synthesized through a number of
different pathways (Basu, 2010), but there appears to be no
evidence for any PGF2α synthesis in T cells. Evidence for a role
of PGF2α signaling in T cells is also very limited, although a recent
study demonstrated a role for this prostaglandin in promoting
Th17 differentiation during allergic lung inflammation (Li et al.,
2011). In this study, the authors propose that PGF2α together with
PGI2 promotes differentiation of Th17 cells – proinflammatory
cells and major contributors in allergic responses – from naïve
CD4+ cells by signaling through their respective receptors in an
autocrine fashion.
LEUKOTRIENES LTA4, LTB4, LTC4, LTD4, LTE4
The first step in leukotriene biosynthesis, conversion of arachi-
donic acid to the unstable epoxide intermediate LTA4, is catalyzed
by 5-LOX, an enzyme shown to occur in human T cell lines as well
as in purified peripheral blood T cells (Cook-Moreau et al., 2007).
5-LOX expression is found across a wide range of T cells, including
naive and memory helper and cytotoxic T cells as well as TCR–γδ
cells (Cook-Moreau et al., 2007). However, some have noted that
T lymphocytes require exogenous arachidonic acid in order to
synthesize leukotrienes (Cook-Moreau et al., 2007). This is inter-
esting in light of the proposed transcellular eicosanoid biosynthesis

























































Lone and Taskén T cell prostaglandin and leukotriene production and action
mechanism, and it has also been shown that LTA4 can act as
the transferred intermediate metabolite in some systems (Folco
and Murphy, 2006; Sala et al., 2010). LTB4 synthesis, which pro-
ceeds through LTA4 hydrolase, and LTC4 synthesis, which proceeds
through LTC4 synthase, both occur in Jurkat T cells upon CD2,
CD3, and CD28 crosslinking (Cook-Moreau et al., 2007). In pri-
mary T cells, synthesis of LTB4 and LTC4 was only found to occur if
cells were stimulated by CD3 crosslinking and supplied with exoge-
nous arachidonic acid (Cook-Moreau et al., 2007). Depending on
the stimulation protocol, others have also detected the production
of LTB4 or the cysteinyl leukotrienes (LTC4, LTD4, LTE4) in various
T cell lines and primary cells (Cifone et al., 1995; Los et al., 1995).
It should be noted that LTD4 and LTE4 are typically generated
extracellularly after export of LTC4 from the producing cell.
LTB4 can signal through either of its two receptors, the
high affinity BLT1 receptor and the low affinity BLT2 receptor
(Yokomizo et al., 1997, 2000), which couple to Gi or Gq to exert
their function (Back et al., 2011). BLT1 is expressed on CD4+
and CD8+ effector T cells, particularly shortly after activation
(Tager et al., 2003; Islam et al., 2006). In peripheral blood T cells in
healthy humans, BLT1 is found on a small fraction of the pop-
ulation, including both helper and cytotoxic T cells as well as
NKT and γδ T cells (Yokomizo et al., 2001; Pettersson et al., 2003;
Islam et al., 2006), and can expand in response to acute inflam-
mation. The BLT2 receptor is more ubiquitously expressed across
tissues, with very high expression levels in the spleen (Yokomizo
et al., 2000). One study found no evidence for BLT2 expres-
sion in naive CD4+ cells or Th0, Th1, or Th2 cells 7 days after
activation (Tager et al., 2003), while others have shown it to be
present on both CD4+ and CD8+ peripheral blood T cells, but
downregulated in response to T cell activation (Yokomizo et al.,
2001).
In T cells, LTB4 is primarily known for its role in chemotaxis,
but it has also been shown to have other functions, for instance
in differentiation and proliferation. In chemotaxis, LTB4 signals
through the BLT1 receptor on CD4+ or CD8+ cells to mediate cell
movement, which is of particular relevance during T cell recruit-
ment to airways and lungs in asthma (Tager et al., 2003; Luster
and Tager, 2004; Gelfand and Dakhanna, 2006), after lung trans-
plants (Medoff et al., 2005) and in various inflammatory settings
(Goodarzi et al., 2003; Ott et al., 2003). In addition, signaling
through BLT1 appears to enable adhesion of T cells to epithe-
lial cells (Tager et al., 2003), which is important for migration
into tissues. In T cell differentiation, LTB4 has been shown to
promote Th17 and inhibit Treg generation, which may be of rele-
vance in autoimmune diseases such as rheumatoid arthritis (Chen
et al., 2009). However, it should be noted that early reports from
1985 had suggested that LTB4 may have an immunoregulatory
role by inducing so-called suppressor T cells (Yamaoka and Kolb,
1993; Morita et al., 1999) but this has not been revisited since
the definition of Treg. Proliferation and cytokine production in T
cells can also be affected by LTB4. In particular, treatment with a
BLT1 antagonist was shown to inhibit cytokine (IL-2, IFN-γ, IL-
4) secretion and proliferation of T cells in response to activation
(Rolapleszczynski, 1985), while LTB4 stimulation enhanced IL-5
production (Gualde et al., 1985), suggesting that LTB4 promotes
T cell activation.
For the cysteinyl leukotrienes LTC4, LTD4, and LTE4, two recep-
tors have been discovered, CysLT1 and CysLT2 (Brink et al., 2003;
Kanaoka and Boyce, 2004; Singh et al., 2010; Back et al., 2011;
Laidlaw and Boyce, 2012). These receptors can bind all the cys-
teinyl leukotrienes, albeit with significantly higher affinity for LTC4
and LTD4 than LTE4 (Laidlaw and Boyce, 2012). Recently, further
receptors involved in cysteinyl leukotriene signaling have been
identified, in particular GPR17, which is a ligand-independent
negative regulator of CysLT1, as well as the LTE4-specific P2Y12
(Austen et al., 2009; Maekawa et al., 2009; Paruchuri et al., 2009;
Laidlaw and Boyce, 2012). While it is unclear whether these latter
two receptors are expressed in T cells, the CysLT1 and CysLT2
receptors have been shown to be expressed in a small fraction of
peripheral blood T cells (Figueroa et al., 2001; Mita et al., 2001).
Activation of the T cells induces higher expression of the CysLT1
receptor (Prinz et al., 2005), as does certain mutations in the linker
for activation of T cells (LAT) (Prinz et al., 2005). It also appears
that expression of this receptor is significantly higher in resting
Th2 cells than in Th1 cells or activated Th2 cells (Parmentier
et al., 2012). Interestingly, both receptors can also be upregulated
in response to inflammatory stimuli. In particular, IL-4 induces
expression of both receptors on T cells, while IFN-γ specifically
upregulates expression of the CysLT2 receptor (Early et al., 2007).
Presumably, this upregulation has the effect of making T cells
more responsive to cysteinyl leukotriene signaling in inflammatory
environments.
There is some functional evidence for a role of cysteinyl
leukotriene signaling in T cells. For one, these molecules appear
to be important in Th2 cells where, as mentioned above, the
CysLT1 receptor is present in significant amounts. It has been
demonstrated that LTE4, through a montelukast-sensitive path-
way, indicating CysLT1 involvement, enhances PGD2-mediated
cytokine secretion in isolated Th2 cells (Xue et al., 2012). In
line with this, another CysLT1 antagonist, pranlukast, inhibits
production of Th2 cytokines, in particular IL-3, IL-4, GM-CSF
and possibly IL-5, from peripheral blood mononuclear cells of
patients with bronchial asthma (Tohda et al., 1999). Further roles
in Th2 cells include a demonstrated effect of LTD4 on the induc-
tion of calcium signaling as well as chemotaxis in these cells, both
processes being CysLT1-specific (Parmentier et al., 2012). Cysteinyl
leukotriene signaling in Th2 cells may also be involved in disease.
For instance, it has been suggested that cysteinyl leukotrienes may
enhance GM-CSF stimulated Th2 functions in atopic asthmatic
patients in vivo (Faith et al., 2008). There has also been a sug-
gested role for the cysteinyl leukotrienes in T cell-mediated late
airway responses to allergen challenge, since treatment with the
CysLT1 antagonist pranlukast inhibits these responses (Hojo et al.,
2000).
CONCLUSION
Eicosanoids are an important class of lipid signaling mediators
and have long been studied for their proinflammatory functions.
In recent years, however, it has become evident that these mole-
cules not only promote inflammation, but can occasionally also act
as anti-inflammatory agents and have more complex and nuanced
roles in the regulation of immune and inflammatory responses.
Here, we have summarized the evidence for the expression of
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and signaling by some important eicosanoids, the AA-derived
prostanoids and the leukotrienes, in T lymphocytes. These lipid
mediators regulate a number of functions in T cells, including pro-
liferation, apoptosis, cytokine secretion, differentiation, chemo-
taxis, and more. Through these processes, eicosanoids regulate a
wide array of physiological processes, ranging from inflammatory
processes such as asthma and allergies, to immune regulation and
involvement in graft rejection, as well as diseases such as can-
cer and AIDS. There is significant interest in targeting some of
these pathways for therapeutic gain and it is therefore crucial to
develop a complete understanding of all the different physiological
functions of these important signaling mediators.
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